Applied Clinical Trials-04-01-2021

FDA Reviews Gains, Risks of Accelerated Approval Process

March 25, 2021

View from Washington

30

4

FDA is reviewing the record of its accelerated approval program following recent withdrawals of certain key indications for several leading cancer therapies, based on the failure of post-approval studies to document extended benefits of treatment.